Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2009

View Archived Issues

EMEA grants orphan drug designation for pixantrone

EMEA recommends withdrawal of benfluorex from the market in E.U.

Sanofia-aventis withdraws MAA for Sliwens for insomnia

FDA extends PDUFA action date for Cephalon's sNDA for Nuvigil

Novartis to acquire Corthera and exclusive worldwide rights to relaxin

Shire submits BLA to the FDA for Replagal, updates Gaucher disease therapy

Encouraging phase I data reported for TRU-016 in relapsed/refractory CLL

Clinical data on pomalidomide in myelofibrosis patients disclosed at ASH meeting

Everolimus shows clinical activity in Waldenstrom's macroglobulinemia and myelofibrosis

Phase I data reported for PD-0332991 plus letrozole in advanced breast cancer

Lactobacillus rhamnosus CGMCC 1.3724 may prevent atopic dermatitis onset

Roche discloses CPT-2 inhibitors for the treatment of type 2 diabetes

Takeda describes tachykinin antagonists for IBS therapy

Wellstat Therapeutics developing URAT1 inhibitors for the treatment of gout

Vitae Pharmaceuticals and Boehringer Ingelheim claim novel antiobesity agents

GlaxoSmithKline presents S1P1 receptor agonists as antiarthritic agents

Arena submits NDA to FDA for lorcaserin for weight management

Biovitrum sells leptin modulator program to AstraZeneca

ImmuneRegen reports efficacy for its new adjuvant of a preventive cancer vaccine

Ligand obtains positive regulatory opinion in Europe for Revolade

Mylan receives tentative FDA approval for efavirenz tablets

PolyMedix completes main portions of phase Ib PMX-30063 study

Resverlogix initiates phase II atherosclerosis clinical trial

Merck to discontinue development of MK-1903 under atherosclerosis program with Arena

Synta initiates phase II study of STA-9090 in metastatic or unresectable GIST

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
CC-3 antibody shows antitumoral activity in penile cancer
BioWorld Science
Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies...